Yonekura S, Okamoto Y, Okubo K, Okawa T, Gotoh M, Suzuki H, Kakuma T, Horiguchi S, Hanazawa T, Konno A, Okuda M
Department of Otolaryngology, Head and Neck Surgery, Graduate School of Medicine, Chiba University, Chiba, Japan.
J Investig Allergol Clin Immunol. 2009;19(3):195-203.
In recent years, many countries have experienced an increase in the prevalence of allergic rhinitis. No effective approach is currently available to prevent the onset of symptoms in allergic individuals. Pranlukast, a leukotriene receptor antagonist with a good safety and efficacy record for the management of allergic inflammation, may be appropriate for early intervention in the management of pollinosis.
To investigate the efficacy of pranlukast as an early intervention in the control of cedar pollinosis.
In a double-blind comparative study, pranlukast (n = 102) or placebo (n = 91) was administered to cedar pollinosis patients immediately before the start of the dispersion season and continued for 4 weeks. Subsequently, pranlukast was administered to all patients for 2 weeks until the end of the cedar pollen dispersion season (mid-March). All patients were carefully monitored for severity of nasal symptoms, symptom scores, medication scores, symptom-medication scores, and quality of life (QOL).
Compared with placebo, therapy with pranlukast before and during the dispersion of cedar pollen in these patients significantly improved nasal symptoms (paroxysmal sneezing, rhinorrhea, and nasal congestion), symptom scores, and symptom-medication scores. The drug also significantly reduced deterioration of QOL, and improved nasal symptoms and QOL throughout the dispersion period.
Administering pranlukast immediately before the beginning of cedar pollen dispersion is effective in reducing symptoms of allergic rhinitis throughout the dispersion period.
近年来，许多国家过敏性鼻炎的患病率呈上升趋势。目前尚无有效的方法可预防过敏个体出现症状。普仑司特是一种白三烯受体拮抗剂，在治疗过敏性炎症方面具有良好的安全性和疗效记录，可能适用于花粉症管理的早期干预。
研究普仑司特作为早期干预措施控制雪松花粉症的疗效。
在一项双盲对照研究中，在雪松花粉散播季节开始前立即给予雪松花粉症患者普仑司特（n = 102）或安慰剂（n = 91），并持续4周。随后，对所有患者给予普仑司特治疗2周，直至雪松花粉散播季节结束（3月中旬）。仔细监测所有患者的鼻部症状严重程度、症状评分、用药评分、症状-用药评分及生活质量（QOL）。
与安慰剂相比，在这些患者中，在雪松花粉散播之前及期间使用普仑司特治疗可显著改善鼻部症状（阵发性喷嚏、流涕和鼻塞）、症状评分及症状-用药评分。该药物还显著减轻了生活质量的恶化，并在整个散播期改善了鼻部症状和生活质量。
在雪松花粉散播开始前立即给予普仑司特可有效减轻整个散播期过敏性鼻炎的症状。
